バイオ医薬品市場レポート：適応症別、クラス別、地域別、2025年～2033年

バイオ医薬品市場の世界市場規模は2024年に3,262億米ドルに達しました。今後、IMARC Groupは、2033年には6,648億米ドルに達し、2025年から2033年にかけて8.2%の成長率（CAGR）を示すと予測しています。同市場は、慢性疾患の増加、バイオ医薬品の大幅な進歩、政府支援とヘルスケア支出の増加、個別化医療と標的治療、バイオシミラーの拡大、人工知能と機械学習の活用の増加によって推進されています。

生物製剤とも呼ばれるバイオ医薬品は、生物由来の医薬品です。バイオ医薬品は、細菌、酵母、哺乳類細胞などの生物を用いて、バイオテクノロジーを駆使して製造されます。化学的に合成される従来の低分子医薬品とは異なり、バイオ医薬品は大きく複雑な分子であり、体内の生物学的標的と極めて特異的な相互作用を示します。バイオ医薬品には、従来の医薬品にはない利点がいくつかあります。バイオ医薬品の作用は特異性が高く、特定の受容体や分子を標的とすることが多いため、有効性が高まり、副作用が軽減されます。さらに、バイオ医薬品は、従来の医薬品では対処が困難であった疾患を治療できる可能性を秘めています。

個別化医療に対する需要の高まりにより、バイオ医薬品市場は大きな成長を遂げています。さらに、がん、糖尿病、乾癬、関節リウマチの治療にバイオ医薬品の利用が増加していることも、成長を促す大きな要因となっています。さらに、バイオ医薬品の有効性と入手可能性に関する大衆の意識の高まりも、成長を促す大きな要因となっています。さらに、希少疾患やオーファンドラッグへの注目の高まりも市場の成長を後押ししています。これらの希少疾患は、患者数が少ないという特徴を持つことが多く、アンメットメディカルニーズが大きいです。これ以外にも、世界中の政府や規制機関が、これらの疾患に対する治療法の開発を奨励するために、インセンティブを導入し、規制プロセスを合理化しています。さらに、バイオ医薬品企業は希少疾病をターゲットとするオーファンドラッグを開発するための研究開発に投資しており、それによって重要な医療ニーズに対応し、市場開拓の機会を創出しています。

バイオ医薬品市場傾向/促進要因：

個別化医療への需要の高まり

個別化医療は、バイオ医薬品市場において標的療法や精密医療へのアプローチへのシフトをもたらしました。バイオ医薬品企業は、疾患に関連する特定の遺伝子変異、バイオマーカー、分子経路を標的とした治療法の開発にますます力を入れるようになっています。さらに、個別化医療は、個人の遺伝的体質が薬物反応にどのように影響するかを研究する薬理ゲノミクスの進歩につながっています。薬物の代謝、有効性、安全性に影響を与える遺伝的変異を理解することで、副作用のリスクがある患者や、特定の治療法に良好な反応を示す可能性が高い患者を特定することができます。この知識により、バイオ医薬品企業は個々の患者に合わせた標的治療や投与レジメンを開発し、治療効果を高め、有害事象のリスクを低減することができます。

慢性疾患と生活習慣病の蔓延

心血管疾患、糖尿病、がん、呼吸器疾患、自己免疫疾患などの慢性疾患は、世界の健康上の大きな課題となっています。これらの疾患は多くの場合、複雑な基礎メカニズムを有しており、標的を絞った個別化治療アプローチが必要とされています。モノクローナル抗体、組換え蛋白質、遺伝子治療などのバイオ医薬品は、正確な標的を定め、オーダーメイドの治療オプションを提供します。これらの治療法は、慢性疾患に関連する特定の分子経路、受容体、細胞を標的とすることができ、その結果、有効性が向上し、副作用が軽減されます。さらに、慢性疾患や生活習慣病による負担の増加により、対症療法から疾患の改善や予防に焦点が移りつつあり、これも市場の成長を後押ししています。

バイオテクノロジーにおける様々な進歩

バイオテクノロジーは創薬・開発プロセスを大幅に加速させています。ハイスループットスクリーニング、コンビナトリアルケミストリー、計算モデリングなどの高度な技術により、短期間で多数の薬剤候補を同定し試験することが可能になった。これにより、創薬の効率とスピードが向上し、バイオ医薬品企業は新しい治療法をより迅速に市場に投入できるようになった。その上、個人の遺伝的体質を分析し、疾患マーカーを特定し、分子経路を理解する能力によって、特定の患者集団に合わせた標的療法の開発が可能になった。ゲノミクス、次世代シーケンシング、遺伝子編集技術などのバイオテクノロジー・ツールは、疾病メカニズムの理解に革命をもたらし、特定の遺伝子変異や分子標的に対処する治療法の開発を可能にしたため、新興国市場を牽引しています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のバイオ医薬品市場

• 市場パフォーマンスと予測
  • 現在のパフォーマンス（2019-2024）
  • 市場予測（2025-2033）
• COVID-19の影響
• 市場：地域別
  • 現在のパフォーマンス（2019-2024）
  • 市場予測（2025-2033）
• 市場：適応症別
  • 自己免疫疾患
  • 腫瘍学
  • 代謝障害
  • その他
• 市場：クラス別
  • 組み換えタンパク質
    • 現在のパフォーマンス（2019-2024）
    • 市場予測（2025-2033）
  • モノクローナル抗体
    • 現在のパフォーマンス（2019-2024）
    • 市場予測（2025-2033）
  • 精製タンパク質
    • 現在のパフォーマンス（2019-2024）
    • 市場予測（2025-2033）
• 競合情勢
  • バイオ医薬品業界のトップ企業
  • トップバイオ医薬品
• バリューチェーン分析
• ポーターのファイブフォース分析
  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • ライバル関係の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第6章 北米

• 米国
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• カナダ
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）

第7章 ラテンアメリカ

• メキシコ
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• ブラジル
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• アルゼンチン
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）

第8章 欧州

• ドイツ
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• フランス
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• イタリア
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• スペイン
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• 英国
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• ロシア
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• トルコ
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）

第9章 アジア太平洋地域

• 日本
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• 中国
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• オーストラリア
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• 韓国
  • 市場パフォーマンス（2019-2024）
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• インド
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）
• インドネシア
  • 市場パフォーマンス（2019-2024）
  • 市場：クラス別
    • 組み換えタンパク質
    • モノクローナル抗体
    • 精製タンパク質
  • 主要企業
  • 市場予測（2025-2033）

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • AbbVie Inc.
  • Amgen Inc
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A

List of Figures

• Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 2: Complexity of Biopharmaceuticals
• Figure 3: Sources of Biopharmaceuticals
• Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion USD), 2019-2024
• Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion USD), 2025-2033
• Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2024
• Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2033
• Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2024
• Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million USD), 2025-2033
• Figure 11: Global: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 13: Global: Recombinant Proteins Market Forecast (in Million USD), 2025-2033
• Figure 14: Global: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million USD), 2025-2033
• Figure 17: Global: Purified Proteins Market (in Million USD), 2019-2024
• Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 19: Global: Purified Proteins Market Forecast (in Million USD), 2025-2033
• Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
• Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
• Figure 22: Global: Biopharmaceutical Industry: Porter's Five Forces Analysis
• Figure 23: United States: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 25: United States: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 27: United States: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 29: United States: Purified Proteins Market (in Million USD), 2019-2024
• Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
• Figure 32: United States: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 34: Canada: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 36: Canada: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 38: Canada: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
• Figure 41: Canada: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 43: Mexico: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 45: Mexico: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 47: Mexico: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 49: Mexico: Purified Proteins Market (in '000 USD), 2019-2024
• Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
• Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 53: Brazil: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 55: Brazil: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 57: Brazil: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 59: Brazil: Purified Proteins Market (in Million USD), 2019-2024
• Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
• Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 63: Argentina: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 65: Argentina: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 67: Argentina: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 69: Argentina: Purified Proteins Market (in Million USD), 2019-2024
• Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 73: Germany: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 75: Germany: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 77: Germany: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 79: Germany: Purified Proteins Market (in Million USD), 2019-2024
• Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 82: Germany: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 84: France: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 86: France: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 88: France: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 90: France: Purified Proteins Market (in Million USD), 2019-2024
• Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
• Figure 92: France: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 94: Italy: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 96: Italy: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 98: Italy: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 100: Italy: Purified Proteins Market (in Million USD), 2019-2024
• Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 102: Italy: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 104: Spain: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 106: Spain: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 108: Spain: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 110: Spain: Purified Proteins Market (in Million USD), 2019-2024
• Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 113: Spain: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 115: UK: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 117: UK: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 119: UK: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 121: UK: Purified Proteins Market (in Million USD), 2019-2024
• Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 124: UK: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 126: Russia: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 128: Russia: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 130: Russia: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 132: Russia: Purified Proteins Market: (in Million USD), 2019-2024
• Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 135: Russia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 137: Turkey: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 139: Turkey: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 142: Turkey: Purified Proteins Market (in Million USD), 2019-2024
• Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 146: Japan: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 148: Japan: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 150: Japan: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 152: Japan: Purified Proteins Market (in Million USD), 2019-2024
• Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million USD), 2025-2033
• Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 156: China: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 158: China: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 160: China: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 162: China: Purified Proteins Market: (in Million USD), 2019-2024
• Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 165: China: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 167: Australia: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 169: Australia: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 171: Australia: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 173: Australia: Purified Proteins Market (in Million USD), 2019-2024
• Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 175: Australia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 177: South Korea: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 179: South Korea: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 181: South Korea: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2024
• Figure 183: South Korea: Purified Proteins Market (in Million USD), 2019-2024
• Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2024
• Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 188: India: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 190: India: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 192: India: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 193: India: Purified Proteins Market (in Million USD), 2019-2024
• Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 195: India: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 197: Indonesia: Biopharmaceutical Market (in Million USD), 2019-2024
• Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
• Figure 199: Indonesia: Recombinant Proteins Market (in Million USD), 2019-2024
• Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
• Figure 201: Indonesia: Monoclonal Antibodies Market (in Million USD), 2019-2024
• Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
• Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
• Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
• Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
• Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
• Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
• Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
• Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
• Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in USD)
• Figure 211: Emerging Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
• Figure 212: Developed Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
• Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
• Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million USD)
• Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

• Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
• Table 2: Global: Biopharmaceutical Market: SWOT Analysis
• Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million USD), 2024 & 2033
• Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
• Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
• Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million USD), 2019-2024
• Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million USD), 2025-2033
• Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion USD), 2024
• Table 9: Mode of Administration of Popular Biotech Drugs

The global biopharmaceutical market size reached USD 326.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 664.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.2% during 2025-2033. The market has been propelled by the increasing prevalence of chronic illnesses, significant advancements in biopharmaceutical, rising government support and healthcare expenditure, personalized medicine and targeted therapies, expansion of biosimilars, and increasing utilization of artificial intelligence and machine learning.

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.

The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.

Biopharmaceutical Market Trends/Drivers:

The escalating demand for personalized medicine

Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.

The growing prevalence of chronic and lifestyle-related diseases

Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.

Various advancements in biotechnology

Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.

Biopharmaceutical Industry Segmentation:

Breakup by Indication:

• Autoimmune Diseases
• Oncology
• Metabolic Disorders
• Others

Autoimmune diseases represent the leading segment

Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.

Breakup by Class:

• Recombinant Proteins
• Monoclonal Antibodies
• Purified Proteins

Monoclonal antibodies exhibit a clear dominance in the market

Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

Breakup by Region:

• North America
• United States
• Canada
• Latin America
• Mexico
• Brazil
• Argentina
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Turkey
• Asia Pacific
• Japan
• China
• Australia
• South Korea
• India
• Indonesia

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.

North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.

Competitive Landscape:

The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AbbVie Inc.
• Amgen Inc
• Biogen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Merck & Co. Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi S.A

Recent Developments:

Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.

Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.

AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Key Questions Answered in This Report

• 1.What was the size of the global biopharmaceutical market in 2024?
• 2.What is the expected growth rate of the global biopharmaceutical market during 2025-2033?
• 3.What are the key factors driving the global biopharmaceutical market?
• 4.What has been the impact of COVID-19 on the global biopharmaceutical market?
• 5.What is the breakup of the global biopharmaceutical market based on the indication?
• 6.What is the breakup of the global biopharmaceutical market based on the class?
• 7.What are the key regions in the global biopharmaceutical market?
• 8.Who are the key players/companies in the global biopharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

• 5.1 Market Performance and Forecast
  • 5.1.1 Current Performance (2019-2024)
  • 5.1.2 Market Forecast (2025-2033)
• 5.2 Impact of COVID-19
• 5.3 Market by Region
  • 5.3.1 Current Performance (2019-2024)
  • 5.3.2 Market Forecast (2025-2033)
• 5.4 Market by Indication
  • 5.4.1 Autoimmune Diseases
  • 5.4.2 Oncology
  • 5.4.3 Metabolic Disorders
  • 5.4.4 Others
• 5.5 Market by Class
  • 5.5.1 Recombinant Proteins
    • 5.5.1.1 Current Performance (2019-2024)
    • 5.5.1.2 Market Forecast (2025-2033)
  • 5.5.2 Monoclonal Antibodies
    • 5.5.2.1 Current Performance (2019-2024)
    • 5.5.2.2 Market Forecast (2025-2033)
  • 5.5.3 Purified Proteins
    • 5.5.3.1 Current Performance (2019-2024)
    • 5.5.3.2 Market Forecast (2025-2033)
• 5.6 Competitive Landscape
  • 5.6.1 Top Biopharmaceutical Players
  • 5.6.2 Top Biopharmaceutical Drugs
• 5.7 Value Chain Analysis
• 5.8 Porter's Five Forces Analysis
  • 5.8.1 Overview
  • 5.8.2 Bargaining Power of Buyers
  • 5.8.3 Bargaining Power of Suppliers
  • 5.8.4 Degree of Rivalry
  • 5.8.5 Threat of New Entrants
  • 5.8.6 Threat of Substitutes

6 North America

• 6.1 United States
  • 6.1.1 Market Performance (2019-2024)
  • 6.1.2 Market by Class
    • 6.1.2.1 Recombinant Proteins
    • 6.1.2.2 Monoclonal Antibodies
    • 6.1.2.3 Purified Proteins
  • 6.1.3 Top Players
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 Canada
  • 6.2.1 Market Performance (2019-2024)
  • 6.2.2 Market by Class
    • 6.2.2.1 Recombinant Proteins
    • 6.2.2.2 Monoclonal Antibodies
    • 6.2.2.3 Purified Proteins
  • 6.2.3 Top Players
  • 6.2.4 Market Forecast (2025-2033)

7 Latin America

• 7.1 Mexico
  • 7.1.1 Market Performance (2019-2024)
  • 7.1.2 Market by Class
    • 7.1.2.1 Recombinant Proteins
    • 7.1.2.2 Monoclonal Antibodies
    • 7.1.2.3 Purified Proteins
  • 7.1.3 Top Players
  • 7.1.4 Market Forecast (2025-2033)
• 7.2 Brazil
  • 7.2.1 Market Performance (2019-2024)
  • 7.2.2 Market by Class
    • 7.2.2.1 Recombinant Proteins
    • 7.2.2.2 Monoclonal Antibodies
    • 7.2.2.3 Purified Proteins
  • 7.2.3 Top Players
  • 7.2.4 Market Forecast (2025-2033)
• 7.3 Argentina
  • 7.3.1 Market Performance (2019-2024)
  • 7.3.2 Market by Class
    • 7.3.2.1 Recombinant Proteins
    • 7.3.2.2 Monoclonal Antibodies
    • 7.3.2.3 Purified Proteins
  • 7.3.3 Top Players
  • 7.3.4 Market Forecast (2025-2033)

8 Europe

• 8.1 Germany
  • 8.1.1 Market Performance (2019-2024)
  • 8.1.2 Market by Class
    • 8.1.2.1 Recombinant Proteins
    • 8.1.2.2 Monoclonal Antibodies
    • 8.1.2.3 Purified Proteins
  • 8.1.3 Top Players
  • 8.1.4 Market Forecast (2025-2033)
• 8.2 France
  • 8.2.1 Market Performance (2019-2024)
  • 8.2.2 Market by Class
    • 8.2.2.1 Recombinant Proteins
    • 8.2.2.2 Monoclonal Antibodies
    • 8.2.2.3 Purified Proteins
  • 8.2.3 Top Players
  • 8.2.4 Market Forecast (2025-2033)
• 8.3 Italy
  • 8.3.1 Market Performance (2019-2024)
  • 8.3.2 Market by Class
    • 8.3.2.1 Recombinant Proteins
    • 8.3.2.2 Monoclonal Antibodies
    • 8.3.2.3 Purified Proteins
  • 8.3.3 Top Players
  • 8.3.4 Market Forecast (2025-2033)
• 8.4 Spain
  • 8.4.1 Market Performance (2019-2024)
  • 8.4.2 Market by Class
    • 8.4.2.1 Recombinant Proteins
    • 8.4.2.2 Monoclonal Antibodies
    • 8.4.2.3 Purified Proteins
  • 8.4.3 Top Players
  • 8.4.4 Market Forecast (2025-2033)
• 8.5 United Kingdom
  • 8.5.1 Market Performance (2019-2024)
  • 8.5.2 Market by Class
    • 8.5.2.1 Recombinant Proteins
    • 8.5.2.2 Monoclonal Antibodies
    • 8.5.2.3 Purified Proteins
  • 8.5.3 Top Players
  • 8.5.4 Market Forecast (2025-2033)
• 8.6 Russia
  • 8.6.1 Market Performance (2019-2024)
  • 8.6.2 Market by Class
    • 8.6.2.1 Recombinant Proteins
    • 8.6.2.2 Monoclonal Antibodies
    • 8.6.2.3 Purified Proteins
  • 8.6.3 Top Players
  • 8.6.4 Market Forecast (2025-2033)
• 8.7 Turkey
  • 8.7.1 Market Performance (2019-2024)
  • 8.7.2 Market by Class
    • 8.7.2.1 Recombinant Proteins
    • 8.7.2.2 Monoclonal Antibodies
    • 8.7.2.3 Purified Proteins
  • 8.7.3 Top Players
  • 8.7.4 Market Forecast (2025-2033)

9 Asia Pacific

• 9.1 Japan
  • 9.1.1 Market Performance (2019-2024)
  • 9.1.2 Market by Class
    • 9.1.2.1 Recombinant Proteins
    • 9.1.2.2 Monoclonal Antibodies
    • 9.1.2.3 Purified Proteins
  • 9.1.3 Top Players
  • 9.1.4 Market Forecast (2025-2033)
• 9.2 China
  • 9.2.1 Market Performance (2019-2024)
  • 9.2.2 Market by Class
    • 9.2.2.1 Recombinant Proteins
    • 9.2.2.2 Monoclonal Antibodies
    • 9.2.2.3 Purified Proteins
  • 9.2.3 Top Players
  • 9.2.4 Market Forecast (2025-2033)
• 9.3 Australia
  • 9.3.1 Market Performance (2019-2024)
  • 9.3.2 Market by Class
    • 9.3.2.1 Recombinant Proteins
    • 9.3.2.2 Monoclonal Antibodies
    • 9.3.2.3 Purified Proteins
  • 9.3.3 Top Players
  • 9.3.4 Market Forecast (2025-2033)
• 9.4 South Korea
  • 9.4.1 Market Performance (2019-2024)
    • 9.4.1.1 Recombinant Proteins
    • 9.4.1.2 Monoclonal Antibodies
    • 9.4.1.3 Purified Proteins
  • 9.4.2 Top Players
  • 9.4.3 Market Forecast (2025-2033)
• 9.5 India
  • 9.5.1 Market Performance (2019-2024)
  • 9.5.2 Market by Class
    • 9.5.2.1 Recombinant Proteins
    • 9.5.2.2 Monoclonal Antibodies
    • 9.5.2.3 Purified Proteins
  • 9.5.3 Top Players
  • 9.5.4 Market Forecast (2025-2033)
• 9.6 Indonesia
  • 9.6.1 Market Performance (2019-2024)
  • 9.6.2 Market by Class
    • 9.6.2.1 Recombinant Proteins
    • 9.6.2.2 Monoclonal Antibodies
    • 9.6.2.3 Purified Proteins
  • 9.6.3 Top Players
  • 9.6.4 Market Forecast (2025-2033)

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Competitive Landscape

• 11.1 Market Structure
• 11.2 Key Players
• 11.3 Profiles of Key Players
  • 11.3.1 AbbVie Inc.
  • 11.3.2 Amgen Inc
  • 11.3.3 Biogen Inc.
  • 11.3.4 Eli Lilly and Company
  • 11.3.5 F. Hoffmann-La Roche AG
  • 11.3.6 Johnson & Johnson
  • 11.3.7 Merck & Co. Inc.
  • 11.3.8 Novo Nordisk A/S
  • 11.3.9 Pfizer Inc.
  • 11.3.10 Sanofi S.A